Answers are grounded in this paper and cite their sources.
The GLP-1 agonists exenatide and liraglutide are promising drugs for inducing weight loss in patients with AIWG. The adverse effects are acceptable, and the addition of GLP-1 does not increase the severity of psychopathology. However, more research is needed.
No takes yet. Share an insight, caveat, or question.
Bak et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: